Angiogenic and Inflammatory Alterations of Endometriotic Lesions in a Transgenic Animal Experimental Model With Loss of Expression of PPAR-Alpha Receptors
article
OA: gold
CC0
⤵ 2 in-corpus citations
Abstract
INTRODUCTION: Peroxisome proliferator-activated receptors (PPARs) have been proposed as a medical treatment against endometriosis in preclinical and clinical studies. Their effect seems to be triggered through the suppression of angiogenesis. In the present study, we used a transgenic animal model with a loss of expression of PPAR-alpha receptors to examine their effect on the course of surgically induced endometriotic lesions.
METHODS: Ten C57BL/6 mice that served as controls and 10 B6;129S4-PPARatm1Gonz/J t transgenic mice characterized by absolute loss of expression of PPAR-alpha receptors were used for induction of endometriosis with a previously described surgical technique.
RESULTS: Five animals (50%) exhibited abundant endometriotic crypts in the control group whereas only one (10%) animal in the transgenic experimental group had a similar pathological image. Neo-vascularization significantly differed among the two groups (p=0.034) favoring the control group as it was extremely limited in half of the PPAR-alpha null animals. The median inflammation score was 2.5 (1-4) in the P B6;129S4-PPARatm1Gonz/J group, whereas it was minimal, 1 (0-2), in the C57BL/6 group. However, these differences were not statistically significant (p=0.101). The fibroblastic activity was also very limited in the PPAR-alpha-deficient model, whereas animals belonging to the control group exhibited an intermediate increase of this index (p=0.022).
CONCLUSION: Surgically induced endometriotic implants in animals with loss of expression of PPAR-alpha receptors exhibit significant differences in their pathology compared to lesions induced in control animals. This information suggests that PPAR-alpha receptors have a significant impact on the course of the disease, indicating that they may serve as potential targets for future medical therapies.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (32)
- A Novel Experimental Model of Colorectal Endometriosis via openalex
- Assessing research gaps and unmet needs in endometriosis via openalex
- Clinical diagnosis of endometriosis: a call to action via openalex
- Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis via openalex
- Endometriosis: Epidemiology, Diagnosis and Clinical Management via openalex
- Endometriosis foci differentiation by rapid lipid profiling using tissue spray ionization and high resolution mass spectrometry via openalex
- Inflammasome as a Key Pathogenic Mechanism in Endometriosis via openalex
- Lipidomic Alterations and PPAR<i>α</i> Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models via openalex
- Pathogenesis of endometriosis: the genetic/epigenetic theory via openalex
- Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α) as a Regulator of the Angiogenic Profile of Endometriotic Lesions via openalex
- PPARγ Activation Inhibits Growth and Survival of Human Endometriotic Cells by Suppressing Estrogen Biosynthesis and PGE2 Signaling. via openalex
- PPARγ Agonists: Emergent Therapy in Endometriosis via openalex
- Resveratrol Enhances Apoptosis in Endometriotic Stromal Cells via openalex
- Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation via openalex
- W2346020725 via openalex
- W2128211963 via openalex
- W2518048292 via openalex
- W2101154974 via openalex
- W2590902226 via openalex
- W2088702580 via openalex
- W2088386132 via openalex
- W2750123393 via openalex
- W2788414583 via openalex
- W2050445005 via openalex
- W1631150466 via openalex
- W3008639564 via openalex
- W3168796739 via openalex
- W1573681132 via openalex
- W7012447 via openalex
- W2157101941 via openalex
- W2168957220 via openalex
- W2288761777 via openalex
Cited by (2)
Source provenance
- europepmc
- last seen: 2026-06-14T06:08:20.186862+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-14T06:07:46.217426+00:00
License: CC0
· commercial use OK